Improving chemoradiation efficacy by PI3-K/AKT inhibition

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• Concurrent chemoradiation is a standard treatment for locally advanced solid tumors, yet patient survival rates remain suboptimal.
• The Phosphatidylinositol 3-kinase (PI3-K)/AKT pathway is frequently activated in tumors, promoting cancer cell survival.
• Hypoxic tumor cells exhibit resistance to both chemotherapy and radiotherapy, contributing to treatment failure.

Purpose of the Study:

• To review the role of PI3-K/AKT signaling in tumor hypoxia and its association with treatment resistance.
• To evaluate the potential of PI3-K/AKT pathway inhibition to enhance chemoradiation efficacy in hypoxic tumors.
• To discuss clinical trials investigating the combination of chemoradiation and PI3-K/AKT inhibitors.

Main Methods:

• Literature review of studies on PI3-K/AKT signaling, hypoxia, and cancer treatment resistance.
• Analysis of preclinical and clinical data regarding PI3-K/AKT pathway inhibitors combined with chemoradiation.
• Exploration of predictive biomarkers for treatment response.

Main Results:

• The PI3-K/AKT pathway is implicated in the survival of hypoxic tumor cells and mediates resistance to chemoradiation.
• Phase I clinical studies have initiated investigations into combining chemoradiation with PI3-K/AKT inhibition for specific cancers.
• Evidence suggests that targeting this pathway could potentially overcome hypoxia-induced treatment resistance.

Conclusions:

• Inhibition of the PI3-K/AKT pathway presents a promising strategy to enhance the effectiveness of chemoradiation in solid tumors, particularly those with hypoxic regions.
• Further clinical investigation is warranted to establish the efficacy and safety of combined chemoradiation and PI3-K/AKT inhibition.
• Development of predictive biomarkers is crucial for patient selection and optimizing treatment outcomes.